RPRX logo

Royalty Pharma plc (RPRX) EBIT

Annual EBIT:

$1.29B-$199.71M(-13.38%)
December 31, 2024

Summary

  • As of today, RPRX annual earnings before interest & taxes is $1.29 billion, with the most recent change of -$199.71 million (-13.38%) on December 31, 2024.
  • During the last 3 years, RPRX annual EBIT has fallen by -$138.27 million (-9.66%).
  • RPRX annual EBIT is now -50.73% below its all-time high of $2.62 billion, reached on December 31, 2019.

Performance

RPRX EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRPRXincome statement metrics

Quarterly EBIT:

$427.16M+$217.36M(+103.60%)
September 30, 2025

Summary

  • As of today, RPRX quarterly earnings before interest & taxes is $427.16 million, with the most recent change of +$217.36 million (+103.60%) on September 30, 2025.
  • Over the past year, RPRX quarterly EBIT has dropped by -$307.92 million (-41.89%).
  • RPRX quarterly EBIT is now -67.93% below its all-time high of $1.33 billion, reached on December 31, 2019.

Performance

RPRX Quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRPRXincome statement metrics

TTM EBIT:

$1.53B-$307.92M(-16.73%)
September 30, 2025

Summary

  • As of today, RPRX TTM earnings before interest & taxes is $1.53 billion, with the most recent change of -$307.92 million (-16.73%) on September 30, 2025.
  • Over the past year, RPRX TTM EBIT has dropped by -$11.79 million (-0.76%).
  • RPRX TTM EBIT is now -41.86% below its all-time high of $2.64 billion, reached on June 30, 2020.

Performance

RPRX TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRPRXincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

RPRX EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-13.4%-41.9%-0.8%
3Y3 Years-9.7%+122.2%+62.5%
5Y5 Years-50.7%-16.3%-41.4%

RPRX EBIT Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-13.4%+40.0%-41.9%+679.0%-19.4%+66.0%
5Y5-Year-50.7%+40.0%-42.7%+679.0%-41.4%+66.0%
All-TimeAll-Time-50.7%+78.8%-67.9%+679.0%-41.9%+255.6%

RPRX EBIT History

DateAnnualQuarterlyTTM
Sep 2025
-
$427.16M(+103.6%)
$1.53B(-16.7%)
Jun 2025
-
$209.80M(-60.7%)
$1.84B(-3.1%)
Mar 2025
-
$534.18M(+48.0%)
$1.90B(+47.1%)
Dec 2024
$1.29B(-13.4%)
$361.00M(-50.9%)
$1.29B(-16.3%)
Sep 2024
-
$735.07M(+172.6%)
$1.54B(+60.8%)
Jun 2024
-
$269.63M(+465.5%)
$960.30M(+2.2%)
Mar 2024
-
-$73.77M(-112.0%)
$939.51M(-37.0%)
Dec 2023
$1.49B(+61.7%)
$613.00M(+304.8%)
$1.49B(+47.4%)
Sep 2023
-
$151.44M(-39.1%)
$1.01B(-3.9%)
Jun 2023
-
$248.84M(-48.0%)
$1.05B(-10.9%)
Mar 2023
-
$478.97M(+260.1%)
$1.18B(+28.1%)
Dec 2022
$922.89M(-35.5%)
$133.00M(-30.8%)
$922.72M(-2.1%)
Sep 2022
-
$192.21M(-49.1%)
$942.72M(-10.5%)
Jun 2022
-
$377.79M(+71.9%)
$1.05B(-25.8%)
Mar 2022
-
$219.72M(+43.6%)
$1.42B(-0.7%)
DateAnnualQuarterlyTTM
Dec 2021
$1.43B(-10.3%)
$153.00M(-49.5%)
$1.43B(-10.1%)
Sep 2021
-
$303.05M(-59.3%)
$1.59B(-11.5%)
Jun 2021
-
$744.95M(+224.9%)
$1.80B(+22.9%)
Mar 2021
-
$229.30M(-27.0%)
$1.46B(-8.3%)
Dec 2020
$1.60B(-39.2%)
$314.00M(-38.5%)
$1.60B(-39.0%)
Sep 2020
-
$510.57M(+24.7%)
$2.61B(-0.8%)
Jun 2020
-
$409.35M(+13.3%)
$2.64B(+3.2%)
Mar 2020
-
$361.43M(-72.9%)
$2.55B(-2.6%)
Dec 2019
$2.62B(+92.3%)
$1.33B(+150.1%)
$2.62B(+103.1%)
Sep 2019
-
$532.50M(+62.4%)
$1.29B(+70.2%)
Jun 2019
-
$327.86M(-23.9%)
$758.76M(+76.1%)
Mar 2019
-
$430.90M
$430.90M
Dec 2018
$1.36B(+45.2%)
-
-
Dec 2017
$939.69M(+30.0%)
-
-
Dec 2016
$722.87M(-9.0%)
-
-
Dec 2015
$794.28M
-
-

FAQ

  • What is Royalty Pharma plc annual earnings before interest & taxes?
  • What is the all-time high annual EBIT for Royalty Pharma plc?
  • What is Royalty Pharma plc annual EBIT year-on-year change?
  • What is Royalty Pharma plc quarterly earnings before interest & taxes?
  • What is the all-time high quarterly EBIT for Royalty Pharma plc?
  • What is Royalty Pharma plc quarterly EBIT year-on-year change?
  • What is Royalty Pharma plc TTM earnings before interest & taxes?
  • What is the all-time high TTM EBIT for Royalty Pharma plc?
  • What is Royalty Pharma plc TTM EBIT year-on-year change?

What is Royalty Pharma plc annual earnings before interest & taxes?

The current annual EBIT of RPRX is $1.29B

What is the all-time high annual EBIT for Royalty Pharma plc?

Royalty Pharma plc all-time high annual earnings before interest & taxes is $2.62B

What is Royalty Pharma plc annual EBIT year-on-year change?

Over the past year, RPRX annual earnings before interest & taxes has changed by -$199.71M (-13.38%)

What is Royalty Pharma plc quarterly earnings before interest & taxes?

The current quarterly EBIT of RPRX is $427.16M

What is the all-time high quarterly EBIT for Royalty Pharma plc?

Royalty Pharma plc all-time high quarterly earnings before interest & taxes is $1.33B

What is Royalty Pharma plc quarterly EBIT year-on-year change?

Over the past year, RPRX quarterly earnings before interest & taxes has changed by -$307.92M (-41.89%)

What is Royalty Pharma plc TTM earnings before interest & taxes?

The current TTM EBIT of RPRX is $1.53B

What is the all-time high TTM EBIT for Royalty Pharma plc?

Royalty Pharma plc all-time high TTM earnings before interest & taxes is $2.64B

What is Royalty Pharma plc TTM EBIT year-on-year change?

Over the past year, RPRX TTM earnings before interest & taxes has changed by -$11.79M (-0.76%)
On this page